Wegovy (semaglutide) tracker
Educational reference for Wegovy (semaglutide). Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
165 h
Tmax
24 h
Category
glp1
> PLACEHOLDER — pending clinical review by licensed pharmacist. Wegovy is Novo Nordisk's brand of semaglutide marketed for chronic weight management.
Mechanism
Wegovy is a brand name for semaglutide, a GLP-1 receptor agonist, at doses used for weight management. See the semaglutide entry for the full mechanism.
Research summary
Wegovy is the semaglutide product approved for chronic weight management (STEP program). See the semaglutide entry for broader context.
Dosing in the literature
Regimens are individualized and set by a prescribing clinician; they are outside the scope of this summary. See the semaglutide entry.
Reported side effects
As a semaglutide product, gastrointestinal effects are most commonly reported; prescribing information includes class warnings. See the semaglutide entry. This is not a complete safety profile.
Stacking notes
See the semaglutide entry. Combination with other agents is a clinical decision.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- Wegovy prescribing information / STEP program · FDA prescribing information (2021)available via DailyMed; see semaglutide entry
References
Track Wegovy (semaglutide) in TrackPep
Reconstitution calculator, interactive body-map rotation, side-effect timeline, weight trends, and a private log — all in one place. Free to try.